182 related articles for article (PubMed ID: 16781242)
1. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
[TBL] [Abstract][Full Text] [Related]
4. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
[TBL] [Abstract][Full Text] [Related]
6. Acute coronary syndromes in Europe: 1-year costs and outcomes.
Taylor MJ; Scuffham PA; McCollam PL; Newby DE
Curr Med Res Opin; 2007 Mar; 23(3):495-503. PubMed ID: 17355731
[TBL] [Abstract][Full Text] [Related]
7. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
[TBL] [Abstract][Full Text] [Related]
10. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
Olsson A; Casciano R; Stern L; Svangren P
Int J Cardiol; 2004 Jul; 96(1):51-7. PubMed ID: 15203261
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention.
Delea TE; Jacobson TA; Serruys PW; Edelsberg JS; Oster G
Ann Pharmacother; 2005 Apr; 39(4):610-6. PubMed ID: 15741421
[TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
[TBL] [Abstract][Full Text] [Related]
13. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
Glasziou PP; Simes RJ; Hall J; Donaldson C
Control Clin Trials; 1997 Oct; 18(5):464-76. PubMed ID: 9315428
[TBL] [Abstract][Full Text] [Related]
14. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD; Berger K; März W; Schäfer JR
Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence.
Thorvik E; Aursnes I; Kristiansen IS; Waaler HT
Wien Klin Wochenschr; 1996; 108(8):234-43. PubMed ID: 8686314
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
Lorenzoni R; Fattore G; Gensini G
G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
[TBL] [Abstract][Full Text] [Related]
20. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
